QNCX: Quince Therapeutics, Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 44.66
Enterprise Value ($M) 52.77
Book Value ($M) 30.15
Book Value / Share 0.69
Price / Book 1.48
NCAV ($M) -40.30
NCAV / Share -0.92
Price / NCAV -1.11

Profitability (mra)
Return on Invested Capital (ROIC) -1.26
Return on Assets (ROA) -0.36
Return on Equity (ROE) -0.77

Liquidity (mrq)
Quick Ratio 6.05
Current Ratio 6.05

Balance Sheet (mrq) ($M)
Current Assets 44.04
Assets 114.48
Liabilities 84.33
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -33.67
Net Income -56.83
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -31.90
Cash from Investing 21.91
Cash from Financing -4.78

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
04-30 13G/A Sofinnova Partners SAS 2.70 -50.05
02-18 13G/A Genextra S.p.A. 6.49 11.11
11-14 13G/A Tang Capital Management Llc 0.00
11-13 13D Lamond David 10.10

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-03-24 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K
2024-11-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q
2024-08-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q
2024-05-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-05-09 42,319 148,471 28.50
2025-05-08 50,087 843,324 5.94
2025-05-07 79,279 715,030 11.09
2025-05-06 173,346 797,182 21.74
2025-05-05 769,579 2,570,598 29.94

(click for more detail)

Similar Companies
PTCT – PTC Therapeutics, Inc. PYXS – Pyxis Oncology, Inc.
QDEL – QuidelOrtho Corporation QURE – uniQure N.V.
RARE – Ultragenyx Pharmaceutical Inc.


Financial data and stock pages provided by
Fintel.io